Three-Pronged attack tested against tough blood cancer
NCT ID NCT04285268
Summary
This study aimed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could help control an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to standard treatments. The trial was designed for adults whose cancer had progressed after at least one prior therapy and who were not candidates for certain other intensive treatments. The goal was to see if this combination could slow or stop cancer growth, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.